TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03542279
Drug: intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG is given 0.4 g/kg/d for each course for 5 days. IVMP is 1,000 mg or 500 mg methylprednisolone for 3 or 5 days, and the dosage of glucocorticoid will gradually decrease.
Study: NCT00112034
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00112034
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02313675
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003459
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)
Study: NCT01181154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: equivalent volume total
Study: NCT02052440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill by mouth three times daily
Study: NCT00306475
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo identical in appearance to active comparator
Study: NCT01333605
Drug: IGEV
Normalized name: Intravenous Immunoglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles.
Study: NCT00090519
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD oral for up to 36 months
Study: NCT00347204
Drug: ketorolac (Acular LS)
Normalized name: ketorolac Ophthalmic Solution [Acular]
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00347204
Drug: Nepafenac (Nevanac)
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01183767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02378649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator concomitant with best practice usual care
Study: NCT04094519
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT03301870
Drug: ATx201 Gel 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% active gel
Study: NCT03301870
Drug: ATx201 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo gel
Study: NCT00715351
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
Study: NCT03115099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03322995
Drug: First-line Chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The first-line therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or best available standard of care.
Study: NCT03322995
Drug: Second-line Chemotherapy
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second line therapies will be multi-agent and contain gemcitabine. Molecular profiling data from the initial endoscopic ultrasound (EUS)/ fine needle aspirate (FNA) biopsy may be used at the discretion of the treating physician.
Study: NCT02261805
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00357994
Drug: Levodopa carbidopa intestinal gel (LCIG)
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
Study: NCT00357994
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00357994
Drug: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00357994
Drug: Placebo (PBO) oral capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03926702
Drug: Radiopharmaceuticals
Normalized name: RADIOPHARMACEUTICALS,DIAGNOSTIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive radiopharmaceutical for positron-emission tomography (PET) scan.
Study: NCT00345046
Drug: EconoPred Plus
Normalized name: Econopred Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone Acetate four times daily decreasing to once daily over four weeks.
Study: NCT00345046
Drug: Prednisolone Acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed four times daily decreasing to once daily over four weeks.
Study: NCT03244800
Drug: MEDI0382
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI0382 will be administered subcutaneously once daily for 49 days.
Study: NCT03244800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously once daily for 49 days.
Study: NCT02897206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An imipenem-matching placebo
Study: NCT01692769
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
Study: NCT01692769
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
Study: NCT04121715
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refer to the Guidelines for Rational Use of Coronary Heart Diseases.rational selection of antiplatelet drugs, statins, etc. according to the patient's condition
Study: NCT01972906
Drug: Ibuprofen Sustained Release Capsules
Normalized name: ibuprofen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: apply Ibuprofen (H20013062), 0.3g， Bid, lasting 3 days before menstrual cycle
Study: NCT03732807
Drug: PF-06651600 Induction Dose
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets taken once daily (QD)
Study: NCT03732807
Drug: PF-06651600 Maintenance Dose #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets taken QD
Study: NCT03732807
Drug: PF-06651600 Maintenance Dose #2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets taken QD
Study: NCT03732807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets taken QD
Study: NCT01779700
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet each day of 8 week cycle
Study: NCT02966652
Drug: DITEST
Normalized name: Meditest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid formulation of native oral testosterone.
Study: NCT03451422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
Study: NCT01115140
Drug: Metformin plus folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metformin 850 mg cp, 2 cps daily plus folic acid 0.4 mg daily
Study: NCT01115140
Drug: placebo plus folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 cp daily plus folic acid 0.4 mg daily
Study: NCT03306498
Drug: Aminoleban (8% amino acids infusion)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 1000ml of AMINOLEBAN contains: Aminoacetic acid - 9.0 g L-alanine -- 7.5 g L-arginine Hydrochloride (HCl) -- 7.3 g (L-arginine equivalent) -- (6.0 g) L-cysteine HCl monohydrate -- 0.4 g (L-cysteine equivalent) -- (0.3 g) L-histidine HCl monohydrate -- 3.2 g (L-histidine equivalent)-- (2.4 g) L-isoleucine -- 9.0 g L-leucine -- 11.0 g L-Lysine HCl -- 7.6 g (L-lysine equivalent) -- (6.1 g) L-methionine -- 1.0 g L-phenylalanine -- 1.0 g L-proline -- 8.0 g L-serine -- 5.0 g L-threonine -- 4.5 g L-tryptophan -- 0.7 g L-valine -- 8.4 g Water for injection q.s -- 1000 m
Study: NCT03274076
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo 5 mg twice a day for 24 weeks
Study: NCT02553889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT03781375
Drug: Placebo to Etanerceot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection twice a week
Study: NCT03781375
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally or subcutaneously once a week at the same dose as prior to study entry
Study: NCT02909959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
Study: NCT04639869
Drug: Cabral 400 mg Film Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.
Study: NCT02973594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03739866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously in the abdomen
Study: NCT00853580
Drug: Lovastatin ™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin starting at 20mg for 2 weeks, increasing to 40mg for 14 weeks. Total duration of trial is 16 weeks.
Study: NCT05427305
Drug: TAB008
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
Study: NCT01359150
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).
Study: NCT01034306
Drug: CF101
Normalized name: CF101
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally q12h
Study: NCT01034306
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally q12 hours
Study: NCT00491894
Drug: Oral Glycopyrrolate Liquid
Normalized name: glycopyrrolate Oral Liquid Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
Study: NCT05340452
Drug: Klaribact 125mg/5ml Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: one single 20 mL dose (500mg) of the test drug will be administered to the volunteers
Study: NCT05340452
Drug: Klaricid 125mg/5ml Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: one single 20 mL dose (500mg) of the Reference drug will be administered to the volunteers
Study: NCT01116206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, orally once dailyfor 12 weeks
Study: NCT04176952
Drug: FOLFOX-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: * nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~* Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~* Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~* Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)
Study: NCT04176952
Drug: AG
Normalized name: AGP
Approvals — FDA: no, EMA: no, PMDA: no
Description: * nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~* Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel).
Study: NCT03717467
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
Study: NCT00587275
Drug: AST-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, sachet, 2 grams daily for 4 weeks
Study: NCT01759862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
Study: NCT00405184
Drug: IntragamP
Approvals — FDA: no, EMA: no, PMDA: no
Description: IntragamP - dosage based on previous dose of IntragamP prior to study entry. One cycle (Cycle 0)only administered, with dosage calculation based on body weight on Day 1 of the study and must be between 0.2-0.8 g/kg body weight. IntragamP to be administered intravenously.
Study: NCT00405184
Drug: Ig NextGen 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ig NextGen 10% - dosage based on previous dose of IntragamP in Cycle 0. Dosage calculation to use body weight on Day 1 of Cycle 1 of the study and must be between 0.2-0.8 g/kg body weight. 7 cycles administered, and patients to be dosed at 3 to 4 week intervals (in accordance with previous dosage schedule with IntragamP). Ig NextGen 10% to be administered intravenously.
Study: NCT04864782
Drug: QL1604
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT01896843
Drug: STX107
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04777383
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iontophoretic administration of 5 different concentrations of acetylcholine
Study: NCT04777383
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iontophoretic administration of 5 different concentrations of norepinephrine
Study: NCT01077700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive substance
Study: NCT03683576
Drug: GB001
Normalized name: Glebretinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated oral tablet
Study: NCT03683576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated oral tablet
Study: NCT01593020
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
Study: NCT01593020
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
Study: NCT02170337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains no active drug
Study: NCT00145470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo fast dissolving SL tablets, BID
Study: NCT03853538
Drug: BAY207543 (Bepanthol, Bepantol® Derma Spray)
Normalized name: Derma Gran Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Product is applied to one hemiface.
Study: NCT04124887
Drug: Xylitol-coated calcium and phosphate
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varnish with Xylitol-coated calcium and phosphate was applied to the targeted teeth at baseline, one and three months.
Study: NCT01044888
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 U/kg heparin was administered intravenously at the beginning of graft anastomosis and accepted a perioperative ACT value of around 300 s. Ten minutes after the loading dose, the ACT was measured. An ACT of 300 s or greater was considered as adequate. Then follow up ACT measurement was determined after 30 min from the previous ACT measurement. If ACT fell below the target value of 300 s, an additional dose of heparin was administered. If ACT was between 250 and 299 s, additional 2000 U of heparin was administered and if ACT was between 200 and 249 s then additional 3000 U of heparin was injected. Ten minutes after additional heparin injection, ACT was remeasured.
Study: NCT04379869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator for double-blind MAD
Study: NCT02063659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching telotristat etiprate tablets
Study: NCT04044781
Drug: BPN14770, T2310
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.
Study: NCT01541059
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of saline solution into the vestibular capsule of each tooth to be extracted.
Study: NCT01000805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received placebo QD, po for 8 weeks.
Study: NCT01800487
Drug: silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg three times a day for 4 weeks
Study: NCT01800487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (silymarin) 1 tab three times a day for 4 weeks
Study: NCT01412736
Drug: KHK4563
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
Study: NCT01412736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
Study: NCT00220805
Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.
Study: NCT00220805
Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
Study: NCT00028548
Drug: R(+)XK469
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00070486
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given PO
Study: NCT00692913
Drug: FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
Study: NCT01064999
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks
Study: NCT00042965
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03158506
Drug: HMS5552
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-labelled HMS5552
Study: NCT00474799
Drug: MNS075
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNS075 7.5mg q1h MNS075 15mg q3h
Study: NCT01752699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
Study: NCT03642834
Drug: ICP-105
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg, 100mg capsule
Study: NCT00653172
Drug: NXL103
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg orally twice daily
Study: NCT00653172
Drug: comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator twice daily
Study: NCT00653172
Drug: NXL103
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg orally twice daily
Study: NCT04055818
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination
Study: NCT05031234
Drug: anaesthesia without opiates
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anaesthesia without opiates for patients undergoing laparoscopic colectomy
Study: NCT01928459
Drug: BGJ398
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.
Study: NCT01928459
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYL719 will be administered orally once daily on each day of the 28-day cycle.
Study: NCT00964236
Drug: Sapropterin
Normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
Study: NCT04160936
Drug: Marcaine Injectable Product
Normalized name: Marcaine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following PCNL under general anesthesia, patients will receive 0.25% Bupivacaine ( Marcaine) local anesthetic infiltration
Study: NCT02328144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days.
Study: NCT01760226
Drug: DA-EPOCH-R for DLBCL, PTLD, AND PMBCL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1: Rituximab IV~Days 1-4: After rituximab, etoposide, vincristine, and doxorubicin will be given in a vein over 96 hours as a continuous infusion.~Day 5: cyclophosphamide will be given in a vein~Days 1-5: prednisone given by mouth twice a day~G-CSF 5mcg/kg/day will be given under the skin from day 6 until ANC has improved.